Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance. The quarter saw substantial revenue growth, encouraging confidence in Gilead ...
Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results, a robust HIV franchise, and an imminent lenacapavir commercialization by summer 2025. Lenacapavir PrEP regimen, with 100% ...
Over the twelve months to December 2024, Gilead Sciences recorded an accrual ratio of -0.27. That implies it has very good cash conversion, and that its earnings in the last year actually ...